BioCryst Presents New ORLADEYO (berotralstat) Data at the 7th Bradykinin Symposium Page 1

RESEARCH TRIANGLE PARK, NC, Sept. 6, 2024 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the presentation of six posters, including the first interim real-world evidence from the APeX-N trial and new data highlighting the value of shared decision-making (SDM) between healthcare providers and their patients with hereditary angioedema (HAE) to provide optimal patient outcomes.

The company will present the posters on the 7^and Bradykinin Symposium in Berlin from 5-6 September 2024.